Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
Newcastle University’s Dr Srikanth Ramaswamy has been announced as one of six new Fellows selected for the 2023 Lister prize
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Subscribe To Our Newsletter & Stay Updated
